Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277496 | 0.79 | MYC (0.43) | MYCKDM4EASPHKDM8KEAP1 | |
| SCHEMBL16277625 | 0.79 | HCRTR1 (0.42) | KDM4ELMNAKMT2AHSD17B10NAPRT | |
| SCHEMBL29628827 | 0.79 | HCRTR1 (0.42) | KDM4ELMNAKMT2AHSD17B10NAPRT | |
| SCHEMBL1672068 | 0.74 | MYC (0.63) | MYCKDM4ESMN1; SMN2KMT2APDE10A | |
| SCHEMBL22288656 | 0.74 | MALT1 (0.43) | MYCKDM4EKMT2A | |
| SCHEMBL1966151 | 0.69 | HDAC1 (0.58) | MYCKDM4ESMN1; SMN2HDAC1KMT2A | |
| SCHEMBL1655468 | 0.69 | MYC (0.56) | MYCKDM4ESMN1; SMN2HDAC1KMT2A | |
| SCHEMBL16463711 | 0.69 | HCRTR1 (0.39) | KDM4EASPHKDM8KEAP1 | |
| SCHEMBL1586067 | 0.68 | ALB (0.50) | NAPRT | |
| SCHEMBL29628873 | 0.68 | ALB (0.50) | NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | MYC 4583/4885KDM4E 1658/4885LMNA 4030/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | MYC 4583/4885KDM4E 1658/4885LMNA 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.